Increased bone mineral density in patients with non-alcoholic steatohepatitis

doi:10.4254/wjh.v5.i11.627

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4035)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-5) series.

Item

Count

PDF

367

HTML

2105

Tables (1-5)

125

Sum=2597

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

747

Download

691

Sum=1438

Nov 27, 2013 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Hepatol. Nov 27, 2013; 5(11): 627-634
Published online Nov 27, 2013. doi: 10.4254/wjh.v5.i11.627

Table 1 Demographic features of patients in the non-alcoholic steatohepatitis and in the control group

Parameter	NASH groupmean ± SD(range)	Control groupmean ± SD(range)	P value
n (Female/Male)	13/25	18/24	0.428
Age (yr)	41 ± 12 (18-69)	42.8 ± 10 (24-65)	0.499
Smoking n (%)	10 (26)	9 (26)	0.810
BMI (kg/m²)	29 ± 4 (20-39)	27 ± 5 (21-39)	0.338
Waist (cm)	98 ± 9 ( 77-118)	93 ± 9 (76-113)	0.019

NASH: Non-alcoholic steatohepatitis; BMI: Body mass index.

Table 2 Biochemical findings of the non-alcoholic steatohepatitis and the control group

Parameter	NASH groupmean ± SD (range)	Control groupmean ± SD (range)	P value
Urea (mg/dL)	28 ± 7 (13-52)	29 ± 8 (14-51)	0.631
Creatinine (mg/dL)	0.7 ± 0.1 (0.6-1.1)	0.8 ± 0.1 (0.5-1.1)	0.631
T. cholesterol (mg/dL)	191 ± 42 (104-314)	187 ± 44 (98-296)	0.668
Triglyceride (mg/dL)	208 ± 210 (67-1420)	136 ± 67 (33-298)	0.008
Calcium (mg/dL)	9.5 ± 0.4 (8.6-10.3)	9.4 ± 0.54 (8.6-10.6)	0.239
Phosphorus (mg/dL)	3.4 ± 0.4 (2.1-4.3)	3.6 ± 0.6(2.3-5.7)	0.288
ALT (U/L)	114 ± 115 (51-775)	20 ± 8 (8-36)	< 0.0001
AST (U/L)	55 ± 31 (28-190)	20 ± 7 (2-35)	< 0.0001
ALP (U/L)	93 ± 44 (43-266)	72 ± 18 (44-123)	0.016
GGT (U/L)	121 ± 214 (23-1135)	29 ± 15 (8-65)	< 0.0001
T bilirubin (mg/dL)	0.8 ± 0.6 (0.2-3.2)	0.6 ± 0.3 (0.2-1.5)	0.165
Albumin (g/dL)	4.2 ± 0.5 (2.3-5.1)	4.2 ± 0.3 (3.5-5.1)	0.214
Ferritin (ng/mL)	208 ± 193 (22-901)	75 ± 82 (3-470)	< 0.001

NASH: Non-alcoholic steatohepatitis; AST: Aspartate transaminase; ALT: Alanine transaminase; GGT: Gamma glutamyl transferase; ALP: Alkaline phosphatase.

Table 3 Serum hormone and cytokine results of the non-alcoholic steatohepatitis and the control group

Parameter	NASH groupmean ± SD (range)	Control group mean ± SD (range)	P value
HOMA	5.7 ± 5.25 (1.1-23.59)	5.6 ± 10.1 (0.7-59.9)	0.192
Cortisol (μg/dL)	12.6 ± 5.8 (1.6-27)	11.6 ± 5.8 (2.9-28)	0.375
TSH (uIU/mL)	1.7 ± 1.09 (0.2-5.3)	1.36 ± 1 (0.01-4)	0.104
FT4 (ng/dL)	1.22 ± 0.19 (0.9-1.8)	1.22 ± 0.22 (0.8-107)	0.999
FSH (mIU/mL)	21 ± 41 (1.6-299)	19 ± 37 (0.3-177)	0.729
LH (mIU/mL)	10.4 ± 10.8 (1.2-44)	11 ± 15 (0.1-64)	0.974
E2 (pg/mL)	39.1 ± 72 (3.8-435)	41 ± 47 (2-199)	0.404
DHEAS (ug/dL)	190 ± 109 (25-501)	146 ± 90 (33-366)	0.071
iPTH (pg/mL)	46.3 ± 20 (18-130)	50 ± 16 (19-105)	0.086
25-OH-vit-D3 (ug/L)	17 ± 6 (5.1-39)	13 ± 7 (3.8-36)	< 0.0001
Testosterone (ng/mL)	2.5 ± 1.9 (0.03-5.8)	1.7 ± 1.9 (0.02-5.4)	0.075
IGF-1 (ng/mL)	141 ± 94 (30-527)	144 ± 47 (67-292)	0.099
TNF-α (pg/mL)	11.6 ± 6.7 (4-31.7)	14 ± 7 (2-4.9)	0.062
IL-6 (pg/mL)	2.2 ± 0.6 (2-4.9)	3 ± 2.4 (2-12)	0.8
IL-1 (pg/mL)	8.2 ± 16.5 (5-107)	5.3 ± 2 (5-17)	0.291
IGFBP-3 (ug/mL)	4.1 ± 1.68 (1.1-8.6)	4.2 ± 0.8 (2.6-6.02)	0.909

NASH: Non-alcoholic steatohepatitis; TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; IGF-1: Insulin-like growth factor-1; IGFBP-3: Insulin-like growth factor binding protein-3; HOMA: Homeostasis model assessment; TSH: Thyroid stimulating hormone; LH: Luteinizing hormone; E2: Estradiol; DHEAS: Dehydroepiandrostenedione sulfate; iPTH: Intact parathormone; FT4: Free T4; FSH: Follicle-stimulating hormone.

Table 4 Histopathological findings according to Brunt classification of liver biopsy obtained from the non-alcoholic steatohepatitis group n (%)

Parameters	Grade 0	Grade 1	Grade 2	Grade 3
Steatosis	0 (0)	11 (29)	15 (39)	12 (32)
Ballooning	1 (3)	11 (29)	26 (68)	-
Lobular inflammation	0 (0)	21 (55)	16 (42)	1 (3)
Portal inflammation	8 (21)	24 (63)	6 (16)	0 (0)
Fibrosis	12 (32)	18 (47)	3 (8)	5 (13)

Table 5 Dual-energy X-ray absorptiometry results of patients in the non-alcoholic steatohepatitis and the control group

Parameter	NASH groupmean ± SD (range)	Control groupmean ± SD (range)	P value
Lumbar BMD	1.057 ± 0.119	0.941 ± 0.133	0.001
Lumbar T-score	-0.77 ± 1.25 (-2.9-2.6)	-1.58 ± 1.36 (-3.7-2.2)	0.009
Lumbar Z-score	-0.44 ± 1.38 (-3.3-2.9)	-1.18 ± 1.28 (-2.9-2.5)	0.019
Femoral BMD	1.004 ± 0.118	0.972 ± 0.130	0.305
Femoral T-score	0.32 ± 0.87 (-2-1.8)	0.062 ± 1.02 (-1.7-2.1)	0.242
Femoral Z-score	0.65 ± 0.92 (-1.5-2.8)	0.35 ± 0.94 (-1.6-2)	0.178

NASH: Non-alcoholic steatohepatitis; BMD: Bone mineral density.

Citation: Kaya M, Işık D, Beştaş R, Evliyaoğlu O, Akpolat V, Büyükbayram H, Kaplan MA. Increased bone mineral density in patients with non-alcoholic steatohepatitis. World J Hepatol 2013; 5(11): 627-634
URL: https://www.wjgnet.com/1948-5182/full/v5/i11/627.htm
DOI: https://dx.doi.org/10.4254/wjh.v5.i11.627